KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBT Margin (2017 - 2025)

Biomarin Pharmaceutical's EBT Margin history spans 16 years, with the latest figure at 3.1% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 2580.0% year-over-year to 3.1%, compared with a TTM value of 14.98% through Dec 2025, down 401.0%, and an annual FY2025 reading of 14.98%, down 401.0% over the prior year.
  • EBT Margin for Q4 2025 was 3.1% at Biomarin Pharmaceutical, up from 3.39% in the prior quarter.
  • The five-year high for EBT Margin was 36.09% in Q2 2025, with the low at 14.8% in Q4 2021.
  • Average EBT Margin over 5 years is 8.94%, with a median of 6.85% recorded in 2023.
  • Year-over-year, EBT Margin surged 2106bps in 2022 and then crashed -2580bps in 2025.
  • Tracing BMRN's EBT Margin over 5 years: stood at 14.8% in 2021, then soared by 78bps to 3.27% in 2022, then skyrocketed by 192bps to 2.99% in 2023, then skyrocketed by 659bps to 22.7% in 2024, then plummeted by -114bps to 3.1% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EBT Margin are 3.1% (Q4 2025), 3.39% (Q3 2025), and 36.09% (Q2 2025).